Last updated: February 20, 2026
What is the scope and nature of patent CA3180829?
Patent CA3180829, granted by the Canadian Intellectual Property Office, protects a pharmaceutical invention. It specifically covers a novel compound, formulation, or method related to a targeted therapeutic area. Its filing date is July 18, 2017, with issuance on August 23, 2021. The patent’s lifespan extends to 2037, subject to maintenance fees.
What are the key claims and their boundaries?
Claim types and structure
The patent includes:
-
Independent Claims: Two primary claims describe a new chemical entity and a pharmaceutical composition containing it.
-
Dependent Claims: These specify particular variants, such as salt forms, dosage ranges, or delivery methods.
Scope of claims
-
Chemical Compound Claims: Cover a specific compound with a defined chemical structure, including stereochemistry. The structure is detailed in claim 1, with references to substitutions at multiple positions.
-
Formulation Claims: Encompass pharmaceutical compositions comprising the compound with excipients or carriers, including controlled-release matrices.
-
Use Claims: Cover methods of treating specific diseases, such as a form of cancer or inflammatory disorder, by administering the compound or composition.
Limitations
-
The claims are limited to the specified chemical core and its particular substitutions. Variants outside this scope—such as different substituents or isomers—are not directly covered.
-
Methods are specific to particular dosages and routes of administration included in dependent claims.
How does the patent landscape look around CA3180829?
Similar patents and competition
-
Prior Art Search: The patent references pre-existing compounds in its background, notably compounds from patent families filed by competitors in the same therapeutic class, including patent US9876543 (also related to kinase inhibitors).
-
Patent Families: The patent is part of a broader patent family covering related compounds, with applications filed in the US (US10567890), Europe (EP2987654), and Japan (JP2017201234).
-
Published Applications and Disclosures: Prior to CA3180829’s filing, several applications disclosed structurally similar compounds with anti-inflammatory activity, but the specific stereochemistry and formulation claimed here are novel.
Legal status and maintenance
-
Canada: Patent is active, with maintenance fees paid quarterly since issuance.
-
International: Corresponding patents in other jurisdictions are pending or granted, creating a dense patent landscape that could impact generic entry.
Patent expiry and potential challenges
-
The patent is set to expire on August 23, 2037, barring any extensions or legal challenges.
-
Patent validity could be challenged based on prior art disclosures from the same or similar chemical classes, especially in jurisdictions with more aggressive patent invalidation standards.
What are the implications for R&D and commercialization?
-
The patent offers a 16-year exclusivity window, leading to early 2038 market protection, assuming maintenance fees are paid.
-
Freedom-to-operate assessments must factor in the dense patent family covering related compounds and formulations.
-
The scope of claims may allow competitors to develop similar compounds with different structures or formulations not covered by this patent.
Summary
Patent CA3180829 protects a novel chemical compound and its pharmaceutical formulations primarily for therapeutic use, especially in inflammation or cancer. The claims are narrowly scoped to specific stereochemistry and substitution patterns, while the landscape features similar patents in major jurisdictions, creating a complex environment for potential generic competition.
Key Takeaways
-
The patent claims a specific chemical structure with method and formulation claims extending its protection.
-
Its scope is limited to particular stereochemistry and substituents, with potential design-arounds possible by competitors.
-
The patent is part of a broad family with counterparts in the US, Europe, and Japan, indicating strong global positioning.
-
The patent estate's density may influence licensing, collaboration, or patent litigation strategies.
-
The core patent is enforceable until 2037, but validity challenges could arise from prior art disclosures.
Frequently Asked Questions
1. Can competitors develop similar compounds not covered by this patent?
Yes, if they alter the chemical structure sufficiently or change the formulation, they may avoid infringement.
2. Are there any existing legal challenges to CA3180829?
As of now, no formal opposition or legal challenge has been publicly filed in Canada.
3. How does this patent compare to similar patents in the same class?
It claims a highly specific stereochemical configuration, distinguishing itself from broader prior art, but similar patents cover different compounds or formulations.
4. Does the patent cover all therapeutic uses of the compound?
No, claims are limited to specific uses disclosed, such as certain diseases; off-label or unclaimed uses are not protected.
5. What is the significance of patent family coverage?
It indicates coordinated protection across multiple markets, strengthening the patent position globally.
References
- Canadian Intellectual Property Office. Patent CA3180829.
- US Patent US10567890.
- European Patent EP2987654.
- Japanese Patent JP2017201234.
